Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:58 PM
Ignite Modification Date:
2025-12-24 @ 2:58 PM
NCT ID:
NCT00703859
Eligibility Criteria:
Inclusion Criteria:
* newly diagnosed GBM
* Diagnosis must be established by open biopsy or tumour resection
* Tumour must have a supratentorial component
* Over 18 years
* pre-treatment evaluations must be met
* study therapy to begin within 6 weeks of surgery
* KPS greater or equal to 70
* patients must sign informed consent
* If female, patients must not be pregnant or lactating
* Women of childbearing potential and male participants must practice adequate contraception
Exclusion Criteria:
* prior invasive malignancy )except for non-melanomatous skin cancer) unless disease free for greater than 3 years
* recurrent or multifocal malignant gliomas
* metastatic disease of leptomeningeal spread
* prior chemo or radiosensitizers for cancers of the head and neck region
* prior RT to head and neck region except for T1 glottic cancer, resulting in overlap of radiation fields.
* Severe active co-morbidity define in protocol
* Pregnant of lactating women
* Women of childbearing potential or men who are sexually active who are not willing or able to use medically acceptable forms of contraception; this exclusion is necessary due to the treatment involved potentially being teratogenic.
* prior allergic reaction to temozolomide and/or dichloroacetate
* History of HIV/AIDS
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00703859
Study Brief:
Protocol Section:
NCT00703859